The State University of New York

Icahn School of Medicine at Mount Sinai

The City University of New York

Ioannis Danias

Oscar A Candia

Rosana Gerometta

Magnus Bergkvist

Alison Gracias

Sara Brenner

Karen Y Torrejon

Hyungsik Lim

Susan Sharfstein

Yubing Xie

Disclosed herein are methods of treatment for an intraocular pressure (IOP)-associated condition in a subject, that include administering to the subject an effective amount of a tissue plasminogen activator (tPA) therapeutic agent. In one embodiment, the IOP-associated condition is glaucoma. The administration of a tPA therapeutic agent can be an extended administration intended to cause a reduction in IOP in the subject for a period of at least one day to a year or more, relative to IOP levels in the subject prior to administration of the tPA therapeutic agent. The tPA therapeutic agent can be, for example, tPA, a tPA derivative, a small molecule direct or indirect tPA agonist, or a gene therapy vector.

Glaucoma treatment

The present invention relates to methods of manufacture and utility of an artificial trabecular meshwork [TM] that utilizes micro- and nanofabricated materials bioengineered to mimic the structure and function of native outflow system of the eye.

Bioengineered human trabecular meshwork for biological applications

The subject matter disclosed herein pertains to a method for screening drugs using second-harmonic generation microscopy. The tissue is scanned with a pulsed laser light which has an excitation wavelength. At least some of microtubules within the tissue produce generated light with a second-harmonic wavelength that is half the excitation wavelength. A microtubule pattern within the tissue is determined based on an analysis of the generated second-harmonic wavelength.

Method for screening a drug in retinal tissue

Growing community of inventors

Staten Island, NY, United States of America

Ioannis Danias